Novo Holdings eyes opportunities as biotech bubble bursts

After years of speculation and premature IPOs, the biotech bubble has burst, says CEO of Novo Holdings Kasim Kutay, who’s now fishing in the troubled waters, saying that the downswing might not last.

Kasim Kutay, CEO of Novo Holdings | Photo: Novo Holdings / PR

In 2021, Novo Holdings could once again report that few life science players are better at making money than the holding company itself, which booked a total income of EUR 5bn in 2021.

While the Novo Nordisk and Novozymes’s stocks have increased markedly last year, the same can’t be said of the general biotech market, which has experienced a violent stock plummet. There has been a drop of over 10 percent on the Nasdaq biotech index, which has also impacted Novo Holdings, according to CEO of Novo Holdings Kasim Kutay.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs